285 related articles for article (PubMed ID: 30542120)
1. Fstl1/DIP2A/MGMT signaling pathway plays important roles in temozolomide resistance in glioblastoma.
Nie E; Miao F; Jin X; Wu W; Zhou X; Zeng A; Yu T; Zhi T; Shi Z; Wang Y; Zhang J; Liu N; You Y
Oncogene; 2019 Apr; 38(15):2706-2721. PubMed ID: 30542120
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of histone deacetylation potentiates the evolution of acquired temozolomide resistance linked to MGMT upregulation in glioblastoma xenografts.
Kitange GJ; Mladek AC; Carlson BL; Schroeder MA; Pokorny JL; Cen L; Decker PA; Wu W; Lomberk GA; Gupta SK; Urrutia RA; Sarkaria JN
Clin Cancer Res; 2012 Aug; 18(15):4070-9. PubMed ID: 22675172
[TBL] [Abstract][Full Text] [Related]
3. NBM-BMX, an HDAC8 Inhibitor, Overcomes Temozolomide Resistance in Glioblastoma Multiforme by Downregulating the β-Catenin/c-Myc/SOX2 Pathway and Upregulating p53-Mediated MGMT Inhibition.
Tsai CY; Ko HJ; Chiou SJ; Lai YL; Hou CC; Javaria T; Huang ZY; Cheng TS; Hsu TI; Chuang JY; Kwan AL; Chuang TH; Huang CF; Loh JK; Hong YR
Int J Mol Sci; 2021 May; 22(11):. PubMed ID: 34072831
[TBL] [Abstract][Full Text] [Related]
4. A novel enhancer regulates MGMT expression and promotes temozolomide resistance in glioblastoma.
Chen X; Zhang M; Gan H; Wang H; Lee JH; Fang D; Kitange GJ; He L; Hu Z; Parney IF; Meyer FB; Giannini C; Sarkaria JN; Zhang Z
Nat Commun; 2018 Jul; 9(1):2949. PubMed ID: 30054476
[TBL] [Abstract][Full Text] [Related]
5. EGFRvIII upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of MGMT promoter methylated glioblastoma.
Struve N; Binder ZA; Stead LF; Brend T; Bagley SJ; Faulkner C; Ott L; Müller-Goebel J; Weik AS; Hoffer K; Krug L; Rieckmann T; Bußmann L; Henze M; Morrissette JJD; Kurian KM; Schüller U; Petersen C; Rothkamm K; O Rourke DM; Short SC; Kriegs M
Oncogene; 2020 Apr; 39(15):3041-3055. PubMed ID: 32066879
[TBL] [Abstract][Full Text] [Related]
6. MGMT Status as a Clinical Biomarker in Glioblastoma.
Butler M; Pongor L; Su YT; Xi L; Raffeld M; Quezado M; Trepel J; Aldape K; Pommier Y; Wu J
Trends Cancer; 2020 May; 6(5):380-391. PubMed ID: 32348734
[TBL] [Abstract][Full Text] [Related]
7. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
[TBL] [Abstract][Full Text] [Related]
8. GADD45A plays a protective role against temozolomide treatment in glioblastoma cells.
Wang HH; Chang TY; Lin WC; Wei KC; Shin JW
Sci Rep; 2017 Aug; 7(1):8814. PubMed ID: 28821714
[TBL] [Abstract][Full Text] [Related]
9. The role of gene body cytosine modifications in MGMT expression and sensitivity to temozolomide.
Moen EL; Stark AL; Zhang W; Dolan ME; Godley LA
Mol Cancer Ther; 2014 May; 13(5):1334-44. PubMed ID: 24568970
[TBL] [Abstract][Full Text] [Related]
10. MEK-ERK signaling dictates DNA-repair gene MGMT expression and temozolomide resistance of stem-like glioblastoma cells via the MDM2-p53 axis.
Sato A; Sunayama J; Matsuda K; Seino S; Suzuki K; Watanabe E; Tachibana K; Tomiyama A; Kayama T; Kitanaka C
Stem Cells; 2011 Dec; 29(12):1942-51. PubMed ID: 21957016
[TBL] [Abstract][Full Text] [Related]
11. TGF-β1 modulates temozolomide resistance in glioblastoma via altered microRNA processing and elevated MGMT.
Nie E; Jin X; Miao F; Yu T; Zhi T; Shi Z; Wang Y; Zhang J; Xie M; You Y
Neuro Oncol; 2021 Mar; 23(3):435-446. PubMed ID: 32813021
[TBL] [Abstract][Full Text] [Related]
12. Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation.
Nguyen SA; Stechishin OD; Luchman HA; Lun XQ; Senger DL; Robbins SM; Cairncross JG; Weiss S
Clin Cancer Res; 2014 Sep; 20(18):4894-903. PubMed ID: 25078279
[TBL] [Abstract][Full Text] [Related]
13. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment.
Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D
J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816
[TBL] [Abstract][Full Text] [Related]
14. Temozolomide Resistance in Glioblastoma Cell Lines: Implication of MGMT, MMR, P-Glycoprotein and CD133 Expression.
Perazzoli G; Prados J; Ortiz R; Caba O; Cabeza L; Berdasco M; Gónzalez B; Melguizo C
PLoS One; 2015; 10(10):e0140131. PubMed ID: 26447477
[TBL] [Abstract][Full Text] [Related]
15. Regulation of expression of O6-methylguanine-DNA methyltransferase and the treatment of glioblastoma (Review).
Cabrini G; Fabbri E; Lo Nigro C; Dechecchi MC; Gambari R
Int J Oncol; 2015 Aug; 47(2):417-28. PubMed ID: 26035292
[TBL] [Abstract][Full Text] [Related]
16. STAT3 inhibition overcomes temozolomide resistance in glioblastoma by downregulating MGMT expression.
Kohsaka S; Wang L; Yachi K; Mahabir R; Narita T; Itoh T; Tanino M; Kimura T; Nishihara H; Tanaka S
Mol Cancer Ther; 2012 Jun; 11(6):1289-99. PubMed ID: 22532597
[TBL] [Abstract][Full Text] [Related]
17. Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2.
Yi GZ; Huang G; Guo M; Zhang X; Wang H; Deng S; Li Y; Xiang W; Chen Z; Pan J; Li Z; Yu L; Lei B; Liu Y; Qi S
Brain; 2019 Aug; 142(8):2352-2366. PubMed ID: 31347685
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of NF-κB results in anti-glioma activity and reduces temozolomide-induced chemoresistance by down-regulating MGMT gene expression.
Yu Z; Chen Y; Wang S; Li P; Zhou G; Yuan Y
Cancer Lett; 2018 Aug; 428():77-89. PubMed ID: 29705182
[TBL] [Abstract][Full Text] [Related]
19. Sulforaphane reverses chemo-resistance to temozolomide in glioblastoma cells by NF-κB-dependent pathway downregulating MGMT expression.
Lan F; Yang Y; Han J; Wu Q; Yu H; Yue X
Int J Oncol; 2016 Feb; 48(2):559-68. PubMed ID: 26648123
[TBL] [Abstract][Full Text] [Related]
20. JNK contributes to temozolomide resistance of stem-like glioblastoma cells via regulation of MGMT expression.
Okada M; Sato A; Shibuya K; Watanabe E; Seino S; Suzuki S; Seino M; Narita Y; Shibui S; Kayama T; Kitanaka C
Int J Oncol; 2014 Feb; 44(2):591-9. PubMed ID: 24316756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
